The Effect of Pranayama Breathing Technique on Asthma Control, Pulmonary Function and Quality of Life
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04110951 |
Recruitment Status :
Completed
First Posted : October 1, 2019
Last Update Posted : October 1, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Asthma | Behavioral: Pranayama Breathing Technique Behavioral: Relaxation technique | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Supportive Care |
Official Title: | The Effect of Pranayama Breathing Technique on Asthma Control, Pulmonary Function and Quality of Life: A Single-Blind Randomized Controlled Trial |
Actual Study Start Date : | February 1, 2018 |
Actual Primary Completion Date : | December 25, 2018 |
Actual Study Completion Date : | May 17, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Pranayama group
Kapalbhati, Ujjayi and Anuloma-Viloma pranayama techniques were applied to the experimental group. Within this scope, a three days of applied training program was prepared and a guide involving the steps of Pranayama breathing technique was formed. The patients in of pranayama group were trained by the researcher who had yoga trainer certificate. After completing three days of training and observations regarding their accomplishment of applications properly, a pranayama breathing technique video showing how the pranayama breathing technique is done with its details was downloaded to their smartphones and a guide including the application steps was distributed to the patients. The patients were required to apply pranayama technique, in company with the video, 20 min every day and a month in total.
|
Behavioral: Pranayama Breathing Technique
Yogic Breathing Technique |
Active Comparator: Relaxation group
As there was not placebo breathing control treatment appropriate to yoga breathing technique, relaxation technique was decided to apply in the second group to equalize psychological effects of the treatment. Progressive relaxation technique was taught to the relaxation group during the same training span.A three days of applied training program and Relaxation Technique Application Guide, including steps of progressive relaxation technique, were prepared within this scope. After completing three days of training and observations regarding their accomplishment of applications properly, a relaxing music to listen during applications and a training video involving progressive relaxation directives were downloaded to smartphones of the patients. Also, Relaxation Technique Application Guide involving application steps were distributed to the patients. The patients were required to apply relaxation technique, in company with the video, 20 min every day and a month in total.
|
Behavioral: Relaxation technique
Progressive relaxation technique |
- Asthma Control Test [ Time Frame: change from baseline score at the end of one month ]Asthma Control Test (ACT) is composed of 5 main sections involving asthma influence level of patients due to daily actions of patients, frequency of asthma symptoms at daytimes and nights, need of urgent relaxing drug, and evaluation of disease by patients. Patients are required to respond each question with values between 1 and 5. Total score of these 5 questions ranges between 5 and 25
- Asthma Quality of Life Questionnaire [ Time Frame: change from baseline score at the end of one month ]Standard Asthma Quality of Life Questionnaire (AQLQ) is a quality of life questionnaire specific to asthma comprising 32 questions. AQLQ was developed by Juniper et al. (1993) to use in clinical studies. The questionnaire evaluates responses through a 7 scores scale (1: severely impaired; 7: not impaired at all) based on changes in last two weeks regarding asthma. Standard AQLQ involves 12 questions about symptoms, 11 questions about activity limitation, 5 questions about emotional functions, and 4 questions about environment stimuli. Mean scores are calculated for subcategories and overall scores. The mean of obtained scores are evaluated between 1 and 7. The minimum score change clinically accepted important in the questionnaire is 0.50 and this situation is called "minimal significant difference" .
- Peak Ekspiratuar Flow [ Time Frame: change from baseline score at the end of one month ]Peak Ekspiratuar Flow (PEF) measurement kind of test which can be accomplished through mobile hand-held tools that enable patients to follow their situations even at their own homes in asthma diagnose and treatment. Repeatability of the test is very high though its application is connected with effort. As PEF measurement gives information about big airways, lower values are obtained in comparison to FEV1 value at 30-50% of the patients. In PEF follow-up, the best PEF value of patient value is primarily defined. Because, the follow-up of patient is conducted in terms of his/her best value not in terms of prediction value indifferent to spirometer in PEF follow-up.
- Forced Expiratory Volume First Second [ Time Frame: change from baseline score at the end of one month ]Forced expiratory volume in first second (FEV1), measured during breathing function test and a flow velocity, is the best indicator of obstruction in asthma. However, FEV1 reflects real obstruction only with powerful and maximum effort as it mostly related with effort.
- Forced Vital Capacity [ Time Frame: change from baseline score at the end of one month ]Effort related part of forced vital capacity (FVC) reflects airways, pulmonary expriratory muscles and the situation of lung elastic recession power.
- FEV1/FVC [ Time Frame: change from baseline score at the end of one month ]FEV1/FVC rate is an important final parameter in defining obstruction as there is not a great change observed in FVC values at early stages of the disease in most of the asthma patients.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Can communicate,
- To have an increase of %12 or 200 ml in FEV1 value after inhaler bronchodilator at breathing function test,
- To have chronic asthma diagnose with 6 months approved by doctors and receiving treatment,
- Asthma controls are not under control or partly under control in relation to GINA (Global Initiative for Asthma) values,
- Taking beta2-agonist and/or ICS twice a week or more to control asthma symptoms,
- There is not any chance in inhaler bronchodilator drug potions during the last four weeks,
- Can use a smart phone.
Exclusion Criteria:
- To have lung diseases such as COPD,
- To have tuberculosis and respiratory infection,
- To have diabetes and coronary artery disease,
- Smokers
- Pregnant or nursing mother,
- Doing regular exercise,
- Benefitng from other complementary and integrative health applications during treatments

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04110951
Turkey | |
Nevşehir Haci Bektaş Veli Üniversitesi | |
Nevşehir, Nerkez, Turkey, 50000 |
Responsible Party: | Gülyeter Erdoğan Yüce, Principal Investigator, TC Erciyes University |
ClinicalTrials.gov Identifier: | NCT04110951 |
Other Study ID Numbers: |
TDK-2017-7652 |
First Posted: | October 1, 2019 Key Record Dates |
Last Update Posted: | October 1, 2019 |
Last Verified: | September 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | There are no plans. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Asthma Yoga Breathing exercises Quality of life Nursing |
Asthma Respiratory Aspiration Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Respiration Disorders Pathologic Processes |